Balyasny Asset Management’s TriSalus Life Sciences Warrant TLSIW Stock Holding History

Balyasny Asset Management’s Portfolio TLSIW Stock Details TLSIW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-95,510	Closed	-$7.59K	–	2788
2023 Q1	$7.59K	Hold	95,510	–	–	﹤0.01%	2513
2022 Q4	$4.78K	Hold	95,510	–	–	﹤0.01%	2625
2022 Q3	$6K	Hold	95,510	–	–	﹤0.01%	2695
2022 Q2	$8K	Hold	95,510	–	–	﹤0.01%	2606
2022 Q1	$24K	Hold	95,510	–	–	﹤0.01%	2334
2021 Q4	$50K	Hold	95,510	–	–	﹤0.01%	2070
2021 Q3	$78K	Hold	95,510	–	–	﹤0.01%	1727
2021 Q2	$95K	Hold	95,510	–	–	﹤0.01%	1807
2021 Q1	$105K	Buy	+95,510	New	+$172K	﹤0.01%	1637

Other funds holding TLSIW

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

ETH

Exos TFP Holdings New York $162M AUM 16.08% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Balyasny Asset Management's TLSIW Position: Q2 2023 in Review

Balyasny Asset Management sold out of TriSalus Life Sciences Warrant (TLSIW) in Q2 2023, closing a stake of 95,510 shares — an estimated $7.59K sold.

Balyasny Asset Management first reported a position in TLSIW in Q1 2021 and held it in 9 quarters. The position peaked at $105K in Q1 2021. 23 funds tracked by Wall St. Rank hold TLSIW as of Q2 2023.

Balyasny Asset Management reported no remaining TriSalus Life Sciences Warrant position as of Q2 2023 after selling out during the quarter.
Balyasny Asset Management sold 95,510 TriSalus Life Sciences Warrant shares in Q2 2023, an estimated $7.59K.
Balyasny Asset Management first reported a position in TriSalus Life Sciences Warrant in Q1 2021 and held it in 9 quarters.
Balyasny Asset Management's TriSalus Life Sciences Warrant position peaked at $105K in Q1 2021.
23 funds tracked by Wall St. Rank held TriSalus Life Sciences Warrant as of Q2 2023.

Based on Balyasny Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.